Press Release: Samumed : Samumed Doses First Subject in Phase 3 STRIDES-X-ray Trial of Lorecivivint for the Treatment of Knee Osteoarthritis

The study will measure clinical and structural effects to assess the disease-modifying capabilities of lorecivivintThe study will measure clinical and structural effects to assess the disease-modifying capabilities of lorecivivint